Skip to main content
Clinical Trials/ACTRN12614000895684
ACTRN12614000895684
Active, not recruiting
未知

MRI inflammation as an imaging biomarker in rheumatoid arthritis: comparing the change in MRI-inflammation scores between patients receiving treatment for disease flare with combination conventional disease suppressing therapy and those commencing combination methotrexate/anti-tumour necrosis factor (TNF) therapy

Prof Fiona McQueen0 sites100 target enrollmentAugust 22, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
rheumatoid arthritis
Sponsor
Prof Fiona McQueen
Enrollment
100
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 22, 2014
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Prof Fiona McQueen

Eligibility Criteria

Inclusion Criteria

  • seropositive rheumatoid arthritis
  • Willing and eligible for disease modifying therapy including methotrexate, combination DAMRDS and /or anti\-TNF therapy as per treating clinician's decision
  • Willing and eligible to have 2 contrast\-enhanced MRI scans (no contraindications)

Exclusion Criteria

  • Contraindications to the medical therapies for rheumatoid arthritis as outlined above
  • Patients will be excluded if there are contraindications to MRI scanning (obesity, claustrophobia, internal metalware) or have impaired renal function and cannot be given IV gadolinium (creatinine clearance must be \> 60ml/min).

Outcomes

Primary Outcomes

Not specified

Similar Trials